Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate Cancer

Inclusion Criteria:

Biopsy proven prostate cancer
Clinical Tumor Category T1b, T1c, T2a and PSA greater than (>) 10 or Gleason score equal or greater than 4+3=7 or PSA velocity > 2.0 ng/ml per year and also eligible patients with tumor category T2c, T3a, T3b, or T4 as per 2002 AJCC guidelines. Any minor tertiary grade of Gleason 5; Biopsy Proven or Radiographic (erMRI Seminal Vesicle Invasion); Gleason = or > 3+4=7 with 50% or more cores positive
Negative bone scan
Lymph node assessment by CT or MR
Adequate hematologic function (Blood Counts)
Adequate liver functions (blood tests)
ECOG performance Status 0 or 1
Peripheral neuropathy must be =< grade 1
PSA obtained within 3 months of entry

Exclusion Criteria:

Prior history of malignancy that are < 5 years except for cancers found to be "in-situ" and would not likely impact a patient's life expectancy with appropriate medical management.
Prior pelvic radiation therapy
Prior hormonal therapy (up to 4 weeks prior to enrollment allowed)
Individuals unable to tolerate lying still 5 - 10 minutes
Patients with a history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 90.